Previous 10 | Next 10 |
The following slide deck was published by Aytu BioScience, Inc. in conjunction with this Read more ...
Aytu BioScience, Inc. (AYTU) Commercial Portfolio Acquisition Overview Conference Call October 14, 2019 4:30 P.M. ET Company Participants Josh Disbrow - Chairman and Chief Executive Officer Conference Call Participants Jeffrey Cohen - Ladenburg Thalmann Carl Byrnes - Northlan...
Aytu BioScience (NASDAQ: AYTU ) has signed an asset purchase agreement to acquire a portfolio of prescription products from Cerecor (NASDAQ: CERC ) (the "Commercial Portfolio"). More news on: Aytu BioScience, Inc., Cerecor Inc., Healthcare stocks news, Read more ...
Transaction increases annual revenue to $44M and is expected to accelerate time to breakeven, following recently announced acquisition of Innovus Pharmaceuticals Total upfront consideration equals 1.4x LTM revenue plus assumption of debt Triples size of Rx product portfolio to ni...
Armistice Capital and Altium Capital jointly participated in financing ENGLEWOOD, CO / ACCESSWIRE / October 14, 2019 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on global commercialization of novel products addressing significant medical needs, is p...
Co-Promotion Expands Physician Promotion of Aytu's Prescription Sleep Aid with Dedicated Specialty Sales Force, into Psychiatry Market, Which Accounted for Over 2.7 Million Zolpidem Tartrate Prescriptions for The Twelve Months Ending August 2019 Aytu's third announced product co-promoti...
Aytu BioScience, Inc. (AYTU) Q4 2019 Earnings Conference Call September 26, 2019 4:30 P.M. ET Company Participants Josh Disbrow - Chairman & Chief Executive Officer David Green - Chief Financial Officer Conference Call Participants Jeffrey Cohen - Ladenburg Thalmann &...
Aytu BioScience (NASDAQ: AYTU ): FY GAAP EPS of -$3.48 misses by $1.33 . More news on: Aytu BioScience, Inc., Earnings news and commentary, Stocks on the move, Healthcare stocks news, , Read more ...
Results Do Not Include September 2019 Definitive Agreement to Acquire Innovus Pharmaceuticals: Combined LTM revenues of over $31M, Diversifies product line by 10x to over 30 products ENGLEWOOD, CO / ACCESSWIRE / September 26, 2019 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty ph...
The following slide deck was published by Aytu BioScience, Inc. in conjunction with this Read more ...
News, Short Squeeze, Breakout and More Instantly...
Company receives proceeds of $3.5 million through exercise of warrants, a portion of which was used to pay down debt Interest rate on new $13.0 million term loan reduced by approximately 350 basis points today, potentially saving the Company $1.3 million over the life of the term loan T...
Phoenix, Arizona and New York, New York--(Newsfile Corp. - May 29, 2024) - Lytham Partners, a leading investor relations and corporate access firm, today announced the schedule for its Spring 2024 Investor Conference taking place virtually on May 30, 2024. More than 40 companies will be available...
DENVER, CO / ACCESSWIRE / May 23, 2024 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced that Josh Disbrow, CEO, will participate in a webcasted fireside chat and host one-on-one meetings with inv...